EG432798 Inhibitors
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Lovastatin | 75330-75-5 | sc-200850 sc-200850A sc-200850B | 5 mg 25 mg 100 mg | $28.00 $88.00 $332.00 | 12 | |
HMG-CoA reductase inhibitor affecting GTPase activity. Lovastatin indirectly influences Rpl27a-ps4 by modulating the mevalonate pathway, potentially altering cellular responses to interferon-beta and defense mechanisms. | ||||||
GGTI 298 | 1217457-86-7 | sc-361184 sc-361184A | 1 mg 5 mg | $189.00 $822.00 | 2 | |
Geranylgeranyltransferase I (GGTase I) inhibitor. GGTI-298 indirectly affects Rpl27a-ps4 by disrupting protein geranylgeranylation, potentially altering cellular responses to interferon-beta and defense mechanisms. | ||||||
JNK Inhibitor VIII | 894804-07-0 | sc-202673 | 5 mg | $267.00 | 2 | |
JNK pathway inhibitor. JNK Inhibitor VIII indirectly influences Rpl27a-ps4 by modulating the JNK pathway, potentially altering cellular responses to interferon-beta and defense mechanisms. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
PI3K inhibitor affecting GTPase activity. Wortmannin indirectly influences Rpl27a-ps4 by targeting PI3K, potentially altering cellular responses to interferon-beta and defense mechanisms. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
p38 MAPK inhibitor. SB203580 indirectly influences Rpl27a-ps4 by modulating the p38 MAPK pathway, potentially altering cellular responses to interferon-beta and defense mechanisms. | ||||||
AZD5363 | 1143532-39-1 | sc-503190 | 5 mg | $309.00 | ||
AKT inhibitor. AZD5363 indirectly affects Rpl27a-ps4 by targeting AKT, potentially altering cellular responses to interferon-beta and defense mechanisms. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $47.00 $145.00 | 51 | |
SRC family kinase inhibitor affecting GTPase activity. Dasatinib indirectly influences Rpl27a-ps4 by modulating SRC family kinases, potentially altering cellular responses to interferon-beta and defense mechanisms. | ||||||
Tipifarnib | 192185-72-1 | sc-364637 | 10 mg | $720.00 | ||
Farnesyltransferase inhibitor. Tipifarnib indirectly affects Rpl27a-ps4 by disrupting protein farnesylation, potentially altering cellular responses to interferon-beta and defense mechanisms. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
JNK pathway inhibitor. SP600125 indirectly influences Rpl27a-ps4 by modulating the JNK pathway, potentially altering cellular responses to interferon-beta and defense mechanisms. | ||||||